MONSEY, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating whether Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx”) has violated the federal securities laws after the company announced that it had decided not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Transitional Drug Add-on Payment Adjustment (TDAPA). Upon this news, Ardelyx shares have so far fallen nearly 30% in tradin ...

Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to preserve patie ...

Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to preserve patien ...

WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Conference, currentl ...

WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Conference, current ...

Group 1: Ardelyx (ARDX) - Ardelyx is a biopharmaceutical company focused on gastrointestinal and cardiorenal treatments, with its leading product Ibsrela generating $28.4 million in revenue in Q1 [2] - Ibsrela's revenue growth is attributed to an increasing number of healthcare providers prescribing the drug, while another product, Xphozah, generated $15 million in the same quarter [2] - The company is expanding its product offerings and plans to enter international markets, indicating that ARDX stock is undervalued and likely to see price corrections soon [3] Group 2: Sirius XM (SIRI) - Sirius XM is a major player in satellite and online radio services, offering over 400 channels and boasting a subscriber base exceeding 30 million [4][5] - The company reported over $2 million in revenue and free cash flow of $132 million in Q1, driven by its growing subscriber count [5] - Sirius XM has established successful partnerships with brands like Hyundai and Genesis, which may lead to further growth opportunities [5] Group 3: Vaalco Energy (EGY) - Vaalco Energy specializes in hydrocarbon exploration and has facilities in Canada, Gabon, and Egypt, benefiting from increased energy demand due to the Russia-Ukraine conflict [6] - The company reported a net income of $7.7 million in its recent quarterly report, a significant increase from $3.4 million in the same quarter last year [6] - Vaalco Energy has resumed production at its Boabab oil field, which has a capacity of 5,000 barrels per day, and is expected to maintain profitability through the end of the year [6]

Core Insights - The article discusses the potential of investing in microcap or small-cap stocks trading under $10, emphasizing the importance of screening for companies with significant business improvements such as revenue and earnings growth [1] Group 1: Investment Criteria - Stocks should trade between $5 to $10 and have at least a Buy rating from analysts [1] - Companies must show a minimum of 10% earnings growth in the latest full year and consistent positive revenue growth over the last three years [1] Group 2: Company Highlights - **Materialise NV (MTLS)**: - The company reported a 10.4% year-over-year revenue increase for 2023, with its medical segment surpassing 100 million euros in revenue [3] - EBITDA increased by 65%, and the company turned a loss of 0.04 euro cent into a profit of 0.11 euro [3] - Analysts rate it as a Strong Buy with a 134% upside potential based on high target prices [3] - **Ardelyx (ARDX)**: - The company specializes in advanced medicine for unmet medical needs, with significant revenue growth driven by its product IBSRELA, which saw sales rise from $15.6 million to $80 million [4][5] - Total revenue reached $124.5 million, and the company reported a net loss of 30 cents per share, an improvement from 42 cents the previous year [5] - Current stock price is around $6 to $7, with a Strong Buy rating and a high target price of $15 [5] - **Sera Prognostics (SERA)**: - The company focuses on women's health diagnostics, reporting revenue growth from $268,000 to $306,000 in 2023 [7] - The bottom line improved from a loss of $1.43 in 2022 to a loss of $1.16 in 2023 [7] - Analysts continue to rate the stock as a Strong Buy, anticipating increased product demand [7]

WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York ...

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [2] - The company has two commercial products approved in the United States: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [2] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [2] Upcoming Events - Michael Raab, President and CEO, and Justin Renz, Chief Financial and Operations Officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on June 5, 2024, at 10:00 A.M. Eastern Time in New York City [1] - A live webcast of the panel presentation will be available on the Ardelyx website, with a replay accessible for 30 days following the event [1]

Core Insights - Ardelyx, Inc. presented new clinical data on IBSRELA® (tenapanor) at the 2024 Digestive Disease Week Conference, highlighting its safety and efficacy for treating irritable bowel syndrome with constipation (IBS-C) in adults [1][2] - The data includes a post hoc analysis from the Phase 3 T3MPO-1 and T3MPO-2 studies, showing clinically meaningful responses to tenapanor regardless of prior medication use [2] - Efficacy of tenapanor was found to be comparable or more pronounced in Hispanic patients compared to non-Hispanic patients [3] Company Overview - Ardelyx is focused on discovering, developing, and commercializing innovative medicines to address significant unmet medical needs [1][12] - The company has two commercial products approved in the U.S.: IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) [12] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships in Japan and Canada [12] Product Information - IBSRELA (tenapanor) is a first-in-class treatment approved by the FDA for IBS-C in adults, acting as a sodium/hydrogen exchanger 3 (NHE3) inhibitor [1][4] - The mechanism of action involves reducing sodium absorption in the intestines, which helps retain water and improve stool consistency [4] - IBS-C affects an estimated 12 million people in the U.S., leading to impaired quality of life and economic burden [5]